88 results about "Nerve Diseases" patented technology

The invention relates to the technical field of early detection of neurological diseases, and discloses an application of a portable three-dimensional eye tracker in cognitive function assessment, comprising: a portable three-dimensional eye tracker used for collecting eye movement data, including fixation time, glancing trajectory, review frequency and eye jump speed; the electroencephalogram acquisition equipment is used for acquiring electroencephalogram data, and the electroencephalogram data comprises alpha wave energy E alpha, beta wave energy E beta and theta wave energy E theta; the heart rate variability monitoring equipment is used for collecting heart rate data, and the heart rate data comprises the ratio RLF / HF of low frequency (LF) to high frequency (HF). The accuracy of cognitive function evaluation is greatly improved through multi-modal data fusion, real-time monitoring and personalized feedback are provided, early discovery of cognitive impairment is facilitated, and the device is high in portability, supports long-term monitoring and testing anytime and anywhere, and is suitable for early detection and continuous evaluation of Alzheimer's diseases.

The invention discloses a transcranial magnetic navigation body surface visualization and autonomous adjustment system. According to the system, a patient head model is reconstructed through the sMRI technology to obtain a reconstructed head model coordinate system, a real head coordinate system under the view angle of a camera is established through the face recognition technology, and two visual visualization schemes are provided: virtual-real mapping of a target spot is realized through a laser holder; a physician is guided to accurately position the transcranial magnetic coil by using an augmented reality technology, and meanwhile, a visual interface is supported to guide a patient to autonomously adjust the position so as to ensure target attachment. The effectiveness of technologies such as transcranial magnetism can be remarkably improved through accurate target fitting, so that deterioration of nerve diseases is delayed, and the health level and life quality of patients are maintained.

The invention relates to a multistage self-anchoring flexible deep brain electrical stimulation electrode and a preparation method thereof, and relates to the technical field of medical instruments. A bionic root system-octopus whisker composite framework including a main electrode base, a second-stage fractal arm and a third-stage self-anchoring tail end is adopted, intelligent materials such as carbon nano tube / PDMS composite fibers, temperature-sensitive PNIPAAm hydrogel and a degradable PLGA-gelatin composite material are fused, and a mechanical lock catch and biological fusion dual-anchoring mechanism is constructed. The distributed electrode array comprises platinum-iridium alloy, graphene / PDMS and a titanium nitride nano electrode, and cross-scale stimulation from the nuclear group level to the single cell level is achieved. The intelligent regulation and control system solves the problems of brain tissue displacement and chronic inflammation through a pressure feedback degradation and flexible interconnection technology. Compared with a traditional product, the contact area of the electrode is increased by 5-8 times, the stimulation precision reaches the single cell level, and the electrode is suitable for long-term deep brain stimulation treatment of nerve diseases such as Parkinson's disease and epilepsy and has remarkable clinical application value.

Glutamine antagonists and their use for treating oncological, immunological, and neurological diseases are disclosed. Also disclosed are methods for treating an oncological, immunological, infectious or neurological disease or disorder, the method comprising administering to a subject in need of treatment thereof a therapeutically effective amount of a glutamine antagonist of the disclosure or the pharmaceutical composition thereof. Also disclosed are methods of enhancing the effects of an immune checkpoint inhibitor, enabling a subject to respond to an immune checkpoint inhibitor, or enabling the toxicity or the dose or number of treatments with an immune checkpoint inhibitor to be reduced, comprising administering to a subject in need of treatment thereof a therapeutically effective amount of a glutamine antagonist of the disclosure or the pharmaceutical composition thereof, and an immune checkpoint inhibitor. Also disclosed are methods for treating an oncological, immunological, infectious or neurological disease or disorder that is refractory to checkpoint inhibitor therapy, the method comprising administering to a subject in need thereof, and having the refractory disease or disorder, a therapeutically effective amount of a glutamine antagonist of the disclosure or the pharmaceutical composition thereof.

According to the lipid nanoparticles and the synthesis method thereof, the lipid nanoparticles comprise lipidosome, curcumin and nicotinamide ribose. The mass ratio of curcumin to nicotinamide ribose ranges from 1: 1 to 1: 10. Adding nicotinamide ribose into water to form a water-phase liquid; adding curcumin into the basic lipid to form an oil-phase liquid; and mixing the oil-phase liquid with the water-phase liquid to form a lipid nanoparticle solution. The medicine can be delivered through the nasal cavity, bypasses the blood brain barrier and directly and quickly enters the brain, has better targeting property on nerve diseases, and can make key components of the medicine directly reach nerves, so that the medicine has a better treatment effect on the nerve diseases.

The present disclosure relates generally to the field of neurological disease treatment, and in particular to devices and methods for treating neurological diseases based on adaptive stimulation, and methods for controlling such devices. In particular, the present disclosure relates generally to a neurological disease adaptive treatment device (10) including an implantable electrode (11) configured to sense neural activity signals and apply electrical stimulation signals, and a processing and stimulation unit (14) connected to the implantable electrode (11). The processing and stimulation unit includes at least a stimulation module (16) configured to generate a stimulation signal delivered by the implantable electrode (11), the stimulation signal characterized by at least one stimulation parameter, an acquisition module (20) configured to record a neural activity signal record of the neural activity signal sensed by the implantable electrode, and a processing module (18). The processing module (18) is configured to process the neural activity signal recordings recorded by the acquisition module (20) based on a first control logic (22) and adjust at least one stimulation parameter (A) based on the at least one neural activity signal recording processed according to the first control logic (22), the first control logic being a function dependent on at least one signal feature (Fi) of the neural activity signal recordings and composed of a plurality of different function elements based on at least one control parameter (Cj), each function element of the plurality of different function elements being associated with a respective range of the at least one signal feature (Fi), and the processing module (18) is configured to process the neural activity signal recordings recorded by the acquisition module (20) based on a second control logic (23) and adjust the at least one control parameter (Cj) of the first control logic (22) based on the at least one neural activity signal recording processed according to the second control logic (23).

A polypeptide linker (2 to 21 amino acids) is connected to a carrier peptide based on the Ioop2 domain of lynx1. The carrier or transporter peptide may be further coupled via the polypeptide linker to a molecule of interest (MOI) or effector agent, such as a protein or protein domain or any other biomolecule (e.g., biomolecules having a molecular weight of 10kDa to 230 kDa). In some embodiments, the complex may be used therapeutically in targeting various neurological disease-causing cellular components.

The invention discloses a traditional Chinese medicine preparation for repairing damaged cranial nerves, which is prepared by mixing gastrodia elata, radix angelicae, radix paeoniae rubra, arisaema cum bile, ligusticum wallichii, fructus viticis, divaricate saposhnikovia root, ligusticum, poria cocos, radix polygoni multiflori preparata, turmeric, silkworm larva, asarum, mint, semen brassicae, achyranthes root, schizonepeta spike, liquorice, Korean monkshood root, scorpion, radix aconiti preparata, earthworm, leech, ground beetle and centipede according to a certain weight ratio. The traditional Chinese medicine composition is simple to prepare, quick to absorb, remarkable in curative effect, long in drug effect duration, free of side effects, high in safety and low in production cost, diseases are relieved in time, and effective restorative treatment is carried out on cranial nerve injury diseases.

The present invention relates to a splice variant of a CERT1 protein that acts as a biomarker for a TDP-43 pathology, in particular motor neuron diseases such as amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD), but also other neurological diseases, such as Alzheimer's disease. In particular, the present invention relates to methods for identifying a splice variant of CERT1 comprising a cryptic peptide sequence, and to related methods of identifying a TDP-43 pathology and / or reduced TDP-43 function in a subject and to methods for predicting whether a therapy is likely to be successful. Also claimed are antibodies binding to the CERT1 splice variant and kits comprising the antibody.

A method of generating MSC-derived exosome populations may include collecting MSC containing material from living tissue, separating desired mononuclear cells from granulocytes, culturing to multiply the cells, separation of desired cells for further multiplication by washing non-adherent cells and culturing adherent cells, repeating as necessary to obtain a suitably pure population of MSCs, culturing the MSCs in culture media containing negative / healing active cytokines interleukin-4 (IL-4) and interleukin-10 (IL-10) and multifunctional cytokine TGF-ß, and isolating the MSC-derived exosome populations. Diverse MSC-derived exosome populations may be generated by altering the cytokine composition of the culture media. The MSC-derived exosome populations may be screened for effectiveness in treatment of Long Covid using in vitro, in vivo, and pre-clinical testing utilizing model organisms. The exosomes may be administered nasally. Successful MSC-derived exosome populations may be further subjected to patient trials to establish efficacy in treatment of Long Covid via nasal administration of the MSC-derived exosome populations to human subjects. Similar methodologies may be employed to establish efficacy of the MSC-derived exosome populations for treatment of other diseases and conditions related to the central nervous system, spinal cord injury, or neurological diseases, such as Alzheimer disease.

The present technology related to a genus of compounds which are prodrugs of arimoclomol. The present technology further relates to compositions comprising the same and methods of treating neurological diseases and disorders by administering said compounds.

The application discloses a cistema brain-computer interface-minimally invasive whole brain nerve signal acquisition and closed-loop control system based on a cerebrospinal fluid channel and a method thereof. The system comprises a flexible cistema interface array, an ultra-wideband wireless energy and data synchronous transmission module, a nerve signal analysis and decoding module, a self-adaptive closed-loop control module and a system integrated control platform. The flexible cistema interface array is implanted in a cerebrospinal fluid cavity in a minimally invasive manner to acquire multi-brain region nerve signals; and the ultra-wideband transmission module realizes energy supply and high-speed bidirectional communication between an implanted body and an extracorporeal device. The application solves the problems of a large trauma, limited coverage and poor signal quality of an existing invasive interface, has the advantages of minimally invasive, wide area coverage, high signal quality and good integration, and is suitable for diagnosis and treatment of neurological diseases such as epilepsy suppression and post-stroke motor function reconstruction.

Provided herein are antibodies and antigen-binding domains that specifically bind to human CD98 and their use in, for example, transport across the blood brain barrier (BBB). Among others, also provided herein are conjugates comprising these anti-CD98 antibodies and antigen-binding fragments, such as the conjugates with GLP-1R agonists, and their uses in, for example, treating or preventing neurological diseases or disorders and / or metabolic diseases or disorders.

The present invention relates to compositions and methods of GDNF fusion polypeptides, wherein the GDNF fusion polypeptides include an Fc domain, an albumin-binding peptide, a fibronectin domain, or a human serum albumin, joined to a GDNF variant either directly or by the way of a linker. The GDNF fusion polypeptides may used to treat metabolic diseases, such as obesity and Type-1 and Type-2 diabetes, and neurological diseases, such as Amyotrophic lateral sclerosis (ALS) and Parkinson's disease.

A dynamic neuropsychological assessment tool according to an embodiment utilizes speech recognition, speech synthesis and machine learning to assess whether a patient is at risk for a neurological disorder, such as Alzheimer's disease. The dynamic neuropsychological assessment tool enables self-administration by a patient. The tool performs pre-test validation operations on the test environment, test equipment, and the patient's capability for performing the test at that time. The tool also enables dynamic modification of a questionnaire presented to the patient while the patient completes the questionnaire. Also provides the dynamic modification of which tests to present the patient with. The modification can be rule based or modified by a provider. The dynamic neuropsychological assessment tool enables providers and administrators to modify and improve tests and validate them using machine learning based on previously completed assessments and results.

[Problem] To provide a prophylactic or therapeutic agent for amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), Huntington's disease (HD), cerebellar ataxia (SCA), degenerative diseases associated with aging or neurological diseases, brain aging, or diseases associated with brain aging, alzheimer's disease (AD), frontotemporal lobe degeneration (FTLD) and an antibody having a higher stability and exhibiting a prophylactic or therapeutic effect. A human monoclonal antibody (anti-human HMGB1 antibody) that specifically binds to human HMGB1 is used as a prophylactic or therapeutic agent for ALS, PD, HD, SCA, degenerative diseases associated with aging, neurological diseases, brain aging, or diseases associated with brain aging, said human monoclonal antibody comprising: a heavy chain CDR1, a heavy chain CDR2, and a heavy chain CDR3 each comprising a specific amino acid sequence; and a light chain CDR1, a light chain CDR2, and a light chain CDR3 comprising a specific amino acid sequence. An antibody in which the light chain complementarity determining region (CDR) 3 of the anti-human HMGB1 antibody has been modified is used.

Provided are multispecific antibodies or antigen binding fragments thereof comprising at least one first antigen-binding region capable of binding specifically to pyroglutamate amyloid-β and a second antigen-binding region capable of binding specifically to transferrin receptor (TfR). Also provided are methods of treating or detecting a neurological disorder and / or delivering a therapeutic or diagnostic agent across the blood-brain barrier. Also described are nucleic acids encoding the antibodies, vectors comprising the nucleic acids, recombinant host cells comprising the nucleic acids and / or vectors, and methods of producing the multispecific antibodies or antigen binding fragments thereof.

Combination therapies comprising oxytocin and gonadotropin releasing hormone are provided. The combinations can be used to treat aging-related neurological diseases or disorders. In addition, downstream effectors of OXT-GnRH combination, including hypothalamic stem / progenitor cells-derived EVs and vesicles containing or loaded with PTMS, can be used to treat aging-related neurological diseases or disorders.

The present invention relates to the use of a culture medium-based method for inducing the specific differentiation of dental stem cells into dopaminergic neurons. The purpose of the present invention is to develop cell applications for treating degenerative neurological diseases and drugs related to the diseases.

The present invention addresses the problem of providing an agent for preventing or treating amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), Huntington's disease (HD), spinocerebellar ataxia (SCA), aging-related degenerative or neurological disease, brain aging, or diseases associated with brain aging, as well as a more stable antibody that exhibits an effect of preventing or treating these diseases, Alzheimer's disease (AD), or frontotemporal lobar degeneration (FTLD). A human monoclonal antibody that specifically binds to human HMGB1, wherein the human monoclonal antibody (anti-human HMGB1 antibody) comprises a heavy chain CDR1, heavy chain CDR2, and heavy chain CDR3 each consisting of a specific amino acid sequence and a light chain CDR1, light chain CDR2, and light chain CDR3 each consisting of a specific amino acid sequence, is used as an agent for preventing or treating ALS, PD, HD, SCA, aging-related degenerative or neurological disease, brain aging, or diseases associated with brain aging. An antibody in which the light chain complementarity determining region (CDR) 3 of the anti-human HMGB1 antibody has been modified is used.

Osmotic blood-tissue barrier opening offers a promising approach to surmounting challenges posed by the blood-brain barrier in the treatment of brain cancer and neurological diseases. By enhancing permeability of any blood-organ barrier, enabling precise targeting, reducing toxicity, being less invasive, and potentially accommodating larger therapeutic molecules, osmotic blood-organ barrier opening represents a valuable strategy in the fight against diseases such as brain cancer and neurological diseases.

The present invention provides, in part, protein-drug conjugates comprising an anti-transferrin receptor (e.g., human transferrin receptor) antigen binding protein (e.g., scFv, Fab) conjugated to a molecular load (e.g., a polynucleotide, liposome, or lipid nanoparticle) for delivery of the molecular load to a target tissue (e.g., brain or muscle). Methods of treating various diseases or disorders, such as neurological or muscular diseases, with the conjugates are provided.

To provide treatment of nerve diseases, in particular Alzheimer's disease in a specific subpopulation having one or more copies of ApoE4 (or ε4) allele.SOLUTION: Disclosed herein is a method for treating and / or preventing Alzheimer's disease in a patient having one or two copies of ApoE4 allele. Also disclosed herein is a composition for treatment and / or prevention. More specifically, disclosed herein is a method for treating or preventing Alzheimer's disease in a patient being heterozygous or homozygous for the ApoE4 allele. In one embodiment, a compound to be administered is represented by Formula I and pharmaceutically acceptable salts, hydrates and solvates. In the formula, AA1 and AA2 are amino acids.SELECTED DRAWING: Figure 1

The present invention relates to methods, kits, and compositions for testing a sample from a subject and determining: i) if said subject is A / A, A / C, or C / C at position 4444 in the Glutamyl-prolyl-tRNA synthetase 1 (EPRS1) gene or mRNA, and / or ii) if said subject expresses only the 1482T version, only the 1482P version, or both the 1482T and 1482P versions, of the EPRS1 protein; and / or iii) if said subject is m6A methylated or m6A unmethylated at A4355 and / or A4464 in said EPRS1 mRNA; and determining that the subject has hypomyelinating leukodystrophy (HLD) or other neurological condition. The present application also relates to a bioinformatic pipeline to assess if m6A-distal single-nucleotide-variations (m6Ad-SNV) affect methylation of DRACH sites.

The present invention relates to a diagnostic composition comprising at least one peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1 (VDELERIRRSILPYGDSMDRIEKDR), SEQ ID NO: 2 (GGAGSLGAGGAFGEA), SEQ ID NO: 35 (GPAGPPGHPGPPGPR), SEQ ID NO: 4 (EGLITLTELADSLLS), SEQ ID NO: 5 (EFQYLTGGLIEPQVH), SEQ ID NO: 6 (SSHMLTDTKTGLHFN), SEQ ID NO: 7 (FIPGPPGPPGPPGPR), SEQ ID NO: 8 (INEAIEQGTIDKALV), SEQ ID NO: 9 (AFGEAAGDRGPYGTDI) and SEQ ID NO: 10 (LITLTELADSLLSRL). Furthermore, the present invention relates to an in vitro method for detecting the presence or absence of a disease selected from the group of bullous pemphigoid, Parkinson's disease, and a neurological disorder comprising testing the binding of at least one peptide as identified in any of the preceding claims for binding to autoantibodies obtained from a subject suspected of suffering from one of said diseases.

A neural disease diagnosis system based on space-time attention and dynamic domain adaptation belongs to the technical field of cross-modal medical data adaptive analysis. It solves the technical problem that there is an urgent need for a new system that can simultaneously fuse multi-modal information, model multi-scale space-time features, and have dynamic domain adaptation capability to improve the accuracy and generalization ability of multi-site neural disease intelligent diagnosis. The system comprises: a data preprocessing module for extracting standardized time series of individual brain regions from fMRI time series data; a dual-channel feature encoding network module for obtaining global features through an attention mechanism; a feature fusion and classification module, wherein a main task classifier performs a main task to predict whether a testee has a neural disease, and a domain task classifier performs a domain task to predict the site to which the testee belongs; and a dynamic balance training module for adjusting the dynamic balance of the main task and the domain task through a dynamic balance control strategy.

The present invention addresses the problem of providing an agent for preventing or treating amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), Huntington's disease (HD), spinocerebellar ataxia (SCA), aging-related degenerative or neurological disease, brain aging, or diseases associated with brain aging, as well as a more stable antibody that exhibits an effect of preventing or treating these diseases, Alzheimer's disease (AD), or frontotemporal lobar degeneration (FTLD). A human monoclonal antibody that specifically binds to human HMGB1, wherein the human monoclonal antibody (anti-human HMGB1 antibody) comprises a heavy chain CDR1, heavy chain CDR2, and heavy chain CDR3 each consisting of a specific amino acid sequence and a light chain CDR1, light chain CDR2, and light chain CDR3 each consisting of a specific amino acid sequence, is used as an agent for preventing or treating ALS, PD, HD, SCA, aging-related degenerative or neurological disease, brain aging, or diseases associated with brain aging. An antibody in which the light chain complementarity determining region (CDR) 3 of the anti-human HMGB1 antibody has been modified is used.

A method for identifying a cerebral edema or a cerebral microhemorrhage in a subject, the method including providing a sample obtained from the subject, comprising a level of one or more biomarkers, wherein the one or more biomarkers comprises one or more GLX-related GAGs, one or more GLX-related PGs, one or more GLX-related GPs, one or more GLX-related GLs, one or more GLX-related GCs, or one or more fragments thereof, or any combination of the aforementioned biomarkers; measuring or detecting the level of the one or more biomarkers in the sample; comparing the level of the one or more biomarkers measured or detected to a reference level for the one or more biomarkers; and identifying the subject as having a cerebral edema or a cerebral microhemorrhage if the level of the one or more of the biomarkers measured or detected from the sample are different than the reference level for the one or more biomarkers.

Novel cyclic peptides, cyclic peptide conjugates and compositions containing them for treating neurological diseases in a subject include an Odorranalectin (OL) sequence or modified OL sequence as a scaffold and a biologically active peptide or protein and / or therapeutic agent conjugated thereto. Methods of treatment of neurological diseases are based on intranasal delivery of a cyclic peptide or cyclic peptide conjugate as described herein. Combinatorial libraries that include a plurality of cyclic peptides have also been developed and can be used to screen for a ligand(s) for a receptor of interest.

Glucose dendrimers synthesized using a hypercore and glucose monosaccharide-based branching units significantly enhances accumulation in neurons in the brain and in retina when administered in vivo, as compared with dendrimers without glucose monosaccharide-based branching units such as PAMAM. Compositions of glucose dendrimers conjugated with one or more therapeutic, prophylactic or diagnostic agents to prevent, treat, or diagnose a disease or disorder in a subject in need thereof, and methods of use thereof, have been developed. The compositions are particularly suited for treating and / or ameliorating diseases or disorders associated with diseased neurons in the eye or the brain. Methods of treating a human subject having or at risk of a neurological disease or disorder are provided.